Cork investment will enable Janssen to meet critical needs of patients around the world.
Some 450 construction jobs and a further 200 permanent jobs are to be created at Janssen Sciences Ireland as part of a €300m expansion.
The expansion plans involve an investment of more than €300m that will increase the existing manufacturing space by an additional 19,100 square metres.
“The pharma industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of our fastest growing sectors,” An Tánaiste and Minister for Business, Enterprise and Innovation Frances Fitzgerald, TD, said.
“This expansion announced today by Janssen is a strong commitment to our country and I wish them continued success.”
A vote of confidence in the south-west region
Janssen Sciences Ireland has operated a biopharmaceutical supply chain facility on its 40 hectare site in Ringaskiddy since 2005.
The proposed expansion project includes the construction of a new manufacturing buidling, expansion of existing warehouses, labs and offices as well as carparking and internal roads.
Construction is expected to take approximately two years, beginning in October 2017. On average, up to 450 people will be employed during the construction period.
A further 200 people will be employed permanently by Janssen once the construction phase is complete.
“This expansion project is a significant vote of confidence in our team and one which will increase our manufacturing footprint very significantly, allowing us to continue to meet critical patient needs in the areas of multiple myeloma, rheumatoid arthritis and Crohn’s disease,” explained Kyran Johnson, general manager of Janssen Supply Chain Ireland.
IDA Ireland CEO Martin Shanahan said that Janssen already has a considerable footprint in Ireland.
“This investment in Ringaskiddy will have a significant economic impact in the south-west region both during the construction phase and when the facility is fully operational,” Shanahan said.